Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.